Summary
University of Bath spinout Revolver Therapeutics has secured a £572,000 funding round led by QantX, with follow-on investment from the UK Innovation & Science Seed Fund (managed by Future Planet Capital) and the University of Bath. The investment will accelerate development of a novel peptide platform targeting transcription factors, proteins long considered “undruggable” using conventional therapies.
Built on research from Professor Jody Mason’s laboratory, Revolver Therapeutics is advancing proprietary cell-penetrating peptides discovered through its Transcription Block Survival platform. The technology overcomes one of the longstanding challenges in cancer drug discovery by delivering therapeutics capable of reaching transcription factors deep within the cell nucleus.
The funding will expand both the platform and its therapeutic pipeline targeting colorectal cancer while demonstrating how university commercialization and technology transfer can help de-risk breakthrough science. The continued follow-on investment from existing investors also reflects growing confidence in the company’s scientific progress and commercial potential.
Read More Here:
Realizing GAP Impact (Mind the GAP Impact Horizons)
| Impact Area | Reported Impact Outcome |
|---|---|
| Validation and Commercialization Outcomes | University-developed Transcription Block Survival platform advanced into a university spinout developing first-in-class peptide therapeutics targeting previously “undruggable” transcription factors |
| Capital Attraction and Strategic Partner Outcomes | £572,000 follow-on funding round led by QantX with continued investment from UK Innovation & Science Seed Fund and the University of Bath |
